对祖先SARS-CoV-2具有结合或中和抗体个体的奥密克戎突破性感染呈允许性
在纵向队列研究中,分析12例奥密克戎突破感染者的感染前血清,采用实验室自建固相结合试验、WHO校准的商业S1结构域结合试验和商业替代中和活性(SNA)试验,均基于Wuhan-Hu-1株刺突蛋白序列。结果显示结合抗体滴度为1:800至1:51,200,SNA阳性10/12(83%),高结合滴度或SNA均非奥密克戎感染/再感染的保护标志。
要点
- 12例奥密克戎突破感染者感染前结合抗体滴度为1:800至1:51,200。
- SNA在10/12(83%)样本中可检出。
- 高结合抗体滴度或SNA均非奥密克戎感染/再感染的保护标志。
核心结论
- 高结合抗体滴度或替代中和活性均非奥密克戎感染/再感染的保护标志。
研究设计与样本
- 纵向队列研究,分析12例奥密克戎突破感染者的感染前血清。
主要发现
- 感染前实验室自建结合试验抗体滴度为1:800至1:51,200。
- 实验室自建结合试验与商业S1结构域WHO校准试验相关性好且定量一致。
- SNA在10/12(83%)样本中可检出。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breakthrough infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has occurred in populations with high vaccination rates. METHODS: In a longitudinal cohort study, pre-breakthrough infection sera for Omicron breakthroughs (n = 12) were analyzed. Assays utilized include a laboratory-developed solid phase binding assay to recombinant spike protein, a commercial assay to the S1 domain of the spike protein calibrated to the World Health Organization (WHO) standard, and a commercial solid-phase surrogate neutralizing activity (SNA) assay. All assays employed spike protein preparations based on sequences from the Wuhan-Hu-1 strain. RESULTS: Pre-breakthrough binding antibody titers ranged from 1:800 to 1:51,200 for the laboratory-developed binding assay, which correlated well and agreed quantitatively with the commercial spike S1 domain WHO calibrated assay. SNA was detected in 10/12 (83%) samples. CONCLUSIONS: Neither high binding titers nor SNA were markers of protection from Omicron infection/re-infection.
引用
- Williams E, Colson J, Valiathan R, et al. Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2. Vaccine. 2022. PMID: 36088193. doi:10.1016/j.vaccine.2022.08.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。